寒痹康汤对实验性关节炎大鼠血清IL32的影响 (1)

《寒痹康汤对实验性关节炎大鼠血清IL32的影响 (1)》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、·目录中文摘要····················································1英文摘要···················································3引言····················································4正文·············································51实验材料与方法····································

2、········51.1实验动物···············································51.2主要试剂···············································51.3主要仪器···············································51.4药物····················································51.5实验方法························

3、······················51.5.1实验动物造模及分组·······························51.5.2给药方法及采样步骤·······································61.5.2.1给药方法·······································61.5.2.2血清样品采样步骤········································61.5.3观察指标························

4、·············71.5.3.1关节肿胀指数····································71.5.3.2血清IL-32·······························71.6统计学方法············································82结果····················································82.1关节肿胀指数观察·································

5、······82.2血清IL-32测定结果·····································83讨论·····················································103.1西医的病因病理及治疗······································103.1.1西医的病因病理··································103.1.2西医治疗现状··································

6、·······11····1.1中医病因病机及治疗·······································121.5.1中医病因病机··········································121.5.2中医治疗现状······································141.2中西医结合治疗··········································151.3外治法·······························

7、···················171.4寒痹康汤临床实验研究进展·································181.5实验性关节炎与类风湿关节炎的关系·························201.5.2.1同属自身免疫介导性疾病··································201.5.2.2病理类型相似································214存在的问题·······································

8、·······211.5.3.1动物实验的局限性··························211.5.3.2药物作用的差异性········································221.5.3.3相关条件限制性·································225